文献速递肿瘤 PET/CT骨显像与常规 SPECT

前列腺癌骨转移中18F-氟化物PET/CT定量参数与生化肿瘤及特异性骨重塑标志物的可重复性

Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases.
PubMed 文献 · EJNMMI Res · 2017-05-15

前瞻性纳入10例经证实骨转移的前列腺癌患者,间隔中位7天行两次18F-氟化物PET/CT,评估最多5个主导索引病灶及全身骨肿瘤负荷的定量参数与同期血/血清骨转换标志物的重测可重复性。SUVmax、SUVmean、FTV50%及TLF的重测系数分别为26%、24%、23%和35%,各生化标志物重测系数为18%至23%,定量18F-氟化物摄取与同期生化骨标志物测量在前列腺癌转移中可重复且重测变异幅度相似。

要点

  • 10例前列腺癌骨转移患者前瞻性行两次18F-氟化物PET/CT,中位间隔7天(范围6-8天)。
  • 索引病灶SUVmax、SUVmean、FTV50%重测系数分别为26%、24%、23%,全身TLF为35%。
  • PSA、ALP、S-骨钙素、S-beta-CTx、1CTP、BAP重测系数分别为19%、23%、18%、22%、18%、23%。

核心结论

  • 定量18F-氟化物摄取与同期生化骨标志物测量在前列腺癌骨转移中可重复,且重测变异幅度相似。

研究设计与样本

  • 前瞻性纳入10例经证实骨转移的前列腺癌患者,每例记录最多5个主导索引病灶及全身18F-氟化物骨肿瘤负荷。
  • 所有患者行两次序列18F-氟化物PET/CT,均为注射后1小时采集;两次检查中位间隔7天(范围6-8天)。
  • 病灶水平PET参数为SUVmax、SUVmean及采用50%阈值VOI的功能性肿瘤体积(FTV50%);全身骨肿瘤负荷TLF采用SUV≥15阈值计算。
  • 每次PET时获取血/血清生化骨转换标志物:PSA、ALP、S-骨钙素、S-beta-CTx、1CTP和BAP。
  • 共评估47个索引病灶,每例骨转移灶数量范围为2-122个。

主要发现

  • 索引病灶SUVmax重测系数为26%,SUVmean为24%,FTV50%为23%,全身骨肿瘤负荷TLF为35%。
  • 生化骨标志物重测系数:PSA为19%,ALP为23%,S-骨钙素为18%,S-beta-CTx为22%,1CTP为18%,BAP为23%。

关键数值与推荐

  • 索引病灶PET参数:SUVmax重测系数26%、SUVmean 24%、FTV50% 23%;全身TLF重测系数35%。
  • 生化标志物重测系数:PSA 19%、ALP 23%、S-骨钙素18%、S-beta-CTx 22%、1CTP 18%、BAP 23%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 18F-fluoride PET/CT exhibits high sensitivity to delineate and measure the extent of bone metastatic disease in patients with prostate cancer. 18F-fluoride PET/CT could potentially replace traditional bone scintigraphy in clinical routine and trials. However, more studies are needed to assess repeatability and biological uptake variation. The aim of this study was to perform test-retest analysis of quantitative PET-derived parameters and blood/serum bone turnover markers at the same time point. Ten patients with prostate cancer and verified bone metastases were prospectively included. All underwent two serial 18F-fluoride PET/CT at 1 h post-injection. Up to five dominant index lesions and whole-body 18F-fluoride skeletal tumour burden were recorded per patient. Lesion-based PET parameters were SUVmax, SUVmean and functional tumour volume applying a VOI with 50% threshold (FTV50%). The total skeletal tumour burden, total lesion 18F-fluoride (TLF), was calculated using a threshold of SUV of ≥15. Blood/serum biochemical bone turnover markers obtained at the time of each PET were PSA, ALP, S-osteocalcin, S-beta-CTx, 1CTP and BAP. RESULTS: A total of 47 index lesions and a range of 2-122 bone metastases per patient were evaluated. Median time between 18F-fluoride PET/CT was 7 days (range 6-8 days). Repeatability coefficients were for SUVmax 26%, SUVmean 24%, FTV50% for index lesions 23% and total skeletal tumour burden (TLF) 35%. Biochemical bone marker repeatability coefficients were for PSA 19%, ALP 23%, S-osteocalcin 18%, S-beta-CTx 22%, 1CTP 18% and BAP 23%. CONCLUSIONS: Quantitative 18F-fluoride uptake and simultaneous biochemical bone markers measurements are reproducible for prostate cancer metastases and show similar magnitude in test-retest variation.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Wassberg C, Lubberink M, Sörensen J, et al. Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases. EJNMMI Res. 2017. PMID: 28508284. doi:10.1186/s13550-017-0289-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。